Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -1.60 | -0.81 | 0.66 |
| FCF Yield | -5.83% | 5.13% | 7.50% | 7.30% |
| EV / EBITDA | -5.80 | -10.58 | 32.37 | 18.48 |
| Quality | ||||
| ROIC | -5.98% | -0.98% | 0.64% | 6.32% |
| Gross Margin | 94.31% | 92.32% | 90.45% | 90.46% |
| Cash Conversion Ratio | 0.83 | 5.10 | 5.10 | 1.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.89% | -10.50% | 0.83% | 5.75% |
| Free Cash Flow Growth | -230.83% | -60.33% | -50.83% | 27.37% |
| Safety | ||||
| Net Debt / EBITDA | 2.77 | 11.55 | -13.67 | -0.88 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 6.56 | 10.90 | 20.34 | 25.00 |
| Cash Conversion Cycle | 29.32 | -78.07 | -124.72 | 45.53 |